Skip to main content
Top
Published in: Pediatric Nephrology 6/2019

01-06-2019 | Educational Review

Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?

Authors: Asmin Andries, Kristien Daenen, François Jouret, Bert Bammens, Djalila Mekahli, Ann Van Schepdael

Published in: Pediatric Nephrology | Issue 6/2019

Login to get access

Abstract

Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in PKD1 or PKD2 genes, is the most common hereditary renal disease. Renal manifestations of ADPKD are gradual cyst development and kidney enlargement ultimately leading to end-stage renal disease. ADPKD also causes extrarenal manifestations, including endothelial dysfunction and hypertension. Both of these complications are linked with reduced nitric oxide levels related to excessive oxidative stress (OS). OS, defined as disturbances in the prooxidant/antioxidant balance, is harmful to cells due to the excessive generation of highly reactive oxygen and nitrogen free radicals. Next to endothelial dysfunction and hypertension, there is cumulative evidence that OS occurs in the early stages of ADPKD. In the current review, we aim to summarize the cardiovascular complications and the relevance of OS in ADPKD and, more specifically, in the early stages of the disease. First, we will briefly introduce the link between ADPKD and the early cardiovascular complications including hypertension. Secondly, we will describe the potential role of OS in the early stages of ADPKD and its possible importance beyond the chronic kidney disease (CKD) effect. Finally, we will discuss some pharmacological agents capable of reducing reactive oxygen species and OS, which might represent potential treatment targets for ADPKD.
Literature
1.
go back to reference Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B (2015) End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clin Outcomes Res 7:65–72CrossRef Brunelli SM, Blanchette CM, Claxton AJ, Roy D, Rossetti S, Gutierrez B (2015) End-stage renal disease in autosomal dominant polycystic kidney disease: a comparison of dialysis-related utilization and costs with other chronic kidney diseases. Clin Outcomes Res 7:65–72CrossRef
2.
go back to reference Cornec-Le Gall E, Torres VE, Harris PC (2017) Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29:1–11 Cornec-Le Gall E, Torres VE, Harris PC (2017) Genetic complexity of autosomal dominant polycystic kidney and liver diseases. J Am Soc Nephrol 29:1–11
3.
go back to reference Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG (1997) PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179–183CrossRefPubMed Qian F, Germino FJ, Cai Y, Zhang X, Somlo S, Germino GG (1997) PKD1 interacts with PKD2 through a probable coiled-coil domain. Nat Genet 16:179–183CrossRefPubMed
4.
go back to reference Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G (1997) Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A 94:6965–6970CrossRefPubMedPubMedCentral Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G (1997) Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A 94:6965–6970CrossRefPubMedPubMedCentral
5.
go back to reference Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE, Harris PC (2016) Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193–1207CrossRefPubMedPubMedCentral Porath B, Gainullin VG, Cornec-Le Gall E, Dillinger EK, Heyer CM, Hopp K, Edwards ME, Madsen CD, Mauritz SR, Banks CJ, Baheti S, Reddy B, Herrero JI, Bañales JM, Hogan MC, Tasic V, Watnick TJ, Chapman AB, Vigneau C, Lavainne F, Audrézet MP, Ferec C, Le Meur Y, Torres VE, Harris PC (2016) Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease. Am J Hum Genet 98:1193–1207CrossRefPubMedPubMedCentral
6.
go back to reference Fick-Brosnahan GM (2013) Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 9:32–36CrossRefPubMed Fick-Brosnahan GM (2013) Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease. Curr Hypertens Rev 9:32–36CrossRefPubMed
7.
go back to reference Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS (2008) Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51:184–191CrossRefPubMed Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS (2008) Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51:184–191CrossRefPubMed
8.
go back to reference Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K (2012) Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 16:622–628CrossRefPubMedPubMedCentral Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K (2012) Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 16:622–628CrossRefPubMedPubMedCentral
9.
go back to reference Halvorson CR, Bremmer MS, Jacobs SC (2010) Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis 3:69–83PubMedPubMedCentral Halvorson CR, Bremmer MS, Jacobs SC (2010) Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment. Int J Nephrol Renovasc Dis 3:69–83PubMedPubMedCentral
10.
go back to reference Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190–193CrossRefPubMed Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190–193CrossRefPubMed
11.
go back to reference Lanktree MB, Chapman AB (2017) New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol 13:750–768CrossRefPubMed Lanktree MB, Chapman AB (2017) New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol 13:750–768CrossRefPubMed
12.
go back to reference Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M (2017) Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:342–347CrossRefPubMed Nowak KL, Farmer H, Cadnapaphornchai MA, Gitomer B, Chonchol M (2017) Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:342–347CrossRefPubMed
14.
go back to reference Wang D, Iversen J, Wilcox CS, Strandgaard S (2003) Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64:1381–1388CrossRefPubMed Wang D, Iversen J, Wilcox CS, Strandgaard S (2003) Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64:1381–1388CrossRefPubMed
15.
go back to reference Wang D, Iversen J, Strandgaard S (2000) Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371–1376PubMed Wang D, Iversen J, Strandgaard S (2000) Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11:1371–1376PubMed
16.
go back to reference Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW (2014) Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol 307:1198–1206CrossRef Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Klawitter J, Abebe KZ, Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians U, Schrier RW (2014) Endothelial dysfunction and oxidative stress in polycystic kidney disease. Am J Physiol Renal Physiol 307:1198–1206CrossRef
17.
go back to reference Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272–1280CrossRef Locatelli F, Canaud B, Eckardt K-U, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18:1272–1280CrossRef
19.
go back to reference Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405CrossRefPubMed Czerska M, Mikołajewska K, Zieliński M, Gromadzińska J, Wąsowicz W (2015) Today’s oxidative stress markers. Med Pr 66:393–405CrossRefPubMed
20.
go back to reference Drozdz D, Kwinta P, Sztefko K, Kordon Z, Drozdz T, Łątka M, Miklaszewska M, Zachwieja K, Rudziński A, Pietrzyk JA (2016) Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxidative Med Cell Longev 2016:7520231 Drozdz D, Kwinta P, Sztefko K, Kordon Z, Drozdz T, Łątka M, Miklaszewska M, Zachwieja K, Rudziński A, Pietrzyk JA (2016) Oxidative stress biomarkers and left ventricular hypertrophy in children with chronic kidney disease. Oxidative Med Cell Longev 2016:7520231
21.
go back to reference Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (2015) Vasopressin and interactive calcium, cyclic AMP and purinergic signaling in polycystic kidney disease. Nat Rev Nephrol 11:451–464CrossRefPubMedPubMedCentral Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE (2015) Vasopressin and interactive calcium, cyclic AMP and purinergic signaling in polycystic kidney disease. Nat Rev Nephrol 11:451–464CrossRefPubMedPubMedCentral
22.
go back to reference Giehl E, Lemos FO, Huang Y, Giordano FJ, Kuo IY, Ehrlich BE (2017) Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress. Eur J Phys 469:1507–1517CrossRef Giehl E, Lemos FO, Huang Y, Giordano FJ, Kuo IY, Ehrlich BE (2017) Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress. Eur J Phys 469:1507–1517CrossRef
23.
24.
go back to reference Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC (2015) Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest 125:607–620CrossRefPubMedPubMedCentral Gainullin VG, Hopp K, Ward CJ, Hommerding CJ, Harris PC (2015) Polycystin-1 maturation requires polycystin-2 in a dose-dependent manner. J Clin Invest 125:607–620CrossRefPubMedPubMedCentral
25.
go back to reference Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6:82–90CrossRefPubMedPubMedCentral Sibal L, Agarwal SC, Home PD, Boger RH (2010) The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 6:82–90CrossRefPubMedPubMedCentral
26.
go back to reference Grover-Páez F, Zavalza-Gómez AB (2009) Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract 84:1–10CrossRefPubMed Grover-Páez F, Zavalza-Gómez AB (2009) Endothelial dysfunction and cardiovascular risk factors. Diabetes Res Clin Pract 84:1–10CrossRefPubMed
27.
go back to reference Wang D, Iversen J, Strandgaard S (1999) Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 36:502–509CrossRefPubMed Wang D, Iversen J, Strandgaard S (1999) Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res 36:502–509CrossRefPubMed
28.
go back to reference Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T (2004) Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43:854–860CrossRefPubMed Kocaman O, Oflaz H, Yekeler E, Dursun M, Erdogan D, Demirel S, Alisir S, Turgut F, Mercanoglu F, Ecder T (2004) Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43:854–860CrossRefPubMed
29.
go back to reference Oflaz H, Alisir S, Buyukaydin B, Kocaman O, Turgut F, Namli S, Pamukcu B, Oncul A, Ecder T (2005) Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 68:2244–2249CrossRefPubMed Oflaz H, Alisir S, Buyukaydin B, Kocaman O, Turgut F, Namli S, Pamukcu B, Oncul A, Ecder T (2005) Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 68:2244–2249CrossRefPubMed
30.
go back to reference Turgut F, Oflaz H, Namli S, Alisir S, Tufan F, Temiz S, Umman S, Ecder T (2007) Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Ren Fail 29:979–984CrossRefPubMed Turgut F, Oflaz H, Namli S, Alisir S, Tufan F, Temiz S, Umman S, Ecder T (2007) Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Ren Fail 29:979–984CrossRefPubMed
31.
go back to reference Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A (2008) Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 3:986–991CrossRefPubMedPubMedCentral Turkmen K, Oflaz H, Uslu B, Cimen AO, Elitok A (2008) Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 3:986–991CrossRefPubMedPubMedCentral
32.
go back to reference Borresen ML, Wang D, Strandgaard S (2007) Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 27:240–246CrossRefPubMed Borresen ML, Wang D, Strandgaard S (2007) Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function. Am J Nephrol 27:240–246CrossRefPubMed
33.
go back to reference Widmer RJ, Lerman A (2014) Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract 2014:291–308 Widmer RJ, Lerman A (2014) Endothelial dysfunction and cardiovascular disease. Glob Cardiol Sci Pract 2014:291–308
34.
go back to reference Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S (2014) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25:2399–2418CrossRefPubMedPubMedCentral Schrier RW, Brosnahan G, Cadnapaphornchai MA, Chonchol M, Friend K, Gitomer B, Rossetti S (2014) Predictors of autosomal dominant polycystic kidney disease progression. J Am Soc Nephrol 25:2399–2418CrossRefPubMedPubMedCentral
35.
36.
go back to reference Seeman T, Dusek J, Vondrichová H, Kyncl M, John U, Misselwitz J, Janda J (2003) Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8:107–110CrossRefPubMed Seeman T, Dusek J, Vondrichová H, Kyncl M, John U, Misselwitz J, Janda J (2003) Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8:107–110CrossRefPubMed
37.
go back to reference Reddy BV, Chapman AB (2017) The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol 32:31–42CrossRefPubMed Reddy BV, Chapman AB (2017) The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol 32:31–42CrossRefPubMed
38.
go back to reference Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275–2282CrossRefPubMed Mekahli D, Woolf AS, Bockenhauer D (2010) Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol 25:2275–2282CrossRefPubMed
39.
go back to reference Schrier RW (2011) Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis 57:811–813CrossRefPubMed Schrier RW (2011) Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis 57:811–813CrossRefPubMed
40.
go back to reference Salih M, Bovee DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ (2017) Urinary renin-angiotensin markers in polycystic kidney disease. Am J Physiol Renal Physiol 313:F874–F881CrossRefPubMed Salih M, Bovee DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ (2017) Urinary renin-angiotensin markers in polycystic kidney disease. Am J Physiol Renal Physiol 313:F874–F881CrossRefPubMed
42.
43.
go back to reference Gabow P, Chapman A, Johnson A, Tangel D, Duley I, Kaehny W, Manco-Johnson M, Schrier R (1990) Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177–1180CrossRefPubMed Gabow P, Chapman A, Johnson A, Tangel D, Duley I, Kaehny W, Manco-Johnson M, Schrier R (1990) Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 38:1177–1180CrossRefPubMed
44.
go back to reference Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA (1994) The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4:1654–1660PubMed Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA (1994) The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 4:1654–1660PubMed
46.
go back to reference Montezano AC, Touyz RM (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44:2–16CrossRef Montezano AC, Touyz RM (2012) Oxidative stress, Noxs, and hypertension: experimental evidence and clinical controversies. Ann Med 44:2–16CrossRef
47.
go back to reference Touyz RM, Briones AM (2011) Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34:5–14CrossRefPubMed Touyz RM, Briones AM (2011) Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res 34:5–14CrossRefPubMed
48.
go back to reference Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369–376CrossRefPubMedPubMedCentral Cadnapaphornchai MA, Masoumi A, Strain JD, McFann K, Schrier RW (2011) Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 6:369–376CrossRefPubMedPubMedCentral
49.
go back to reference Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192–1196CrossRefPubMedPubMedCentral Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW (2008) Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74:1192–1196CrossRefPubMedPubMedCentral
50.
go back to reference Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E (1993) Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1451–1457 Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E (1993) Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1451–1457
51.
go back to reference Kocyigit I, Kaya MG, Orscelik O, Kaya C, Akpek M, Zengin H, Sipahioglu MH, Unal A, Yilmaz MI, Tokgoz B, Oymak O, Axelsson J (2012) Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 26:11–18 Kocyigit I, Kaya MG, Orscelik O, Kaya C, Akpek M, Zengin H, Sipahioglu MH, Unal A, Yilmaz MI, Tokgoz B, Oymak O, Axelsson J (2012) Early arterial stiffness and inflammatory bio-markers in normotensive polycystic kidney disease patients. Am J Nephrol 26:11–18
52.
go back to reference Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW (1997) Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:1292–1297 Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW (1997) Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:1292–1297
53.
go back to reference Pietrzak-Nowacka M, Safranow K, Czechowska M, Dutkiewicz G, Kornacewicz-Jach Z, Ciechanowski K (2012) Autosomal dominant polycystic kidney disease and hypertension are associated with left ventricular mass in a gender-dependent manner. Kidney Blood Press Res 36:301–309 Pietrzak-Nowacka M, Safranow K, Czechowska M, Dutkiewicz G, Kornacewicz-Jach Z, Ciechanowski K (2012) Autosomal dominant polycystic kidney disease and hypertension are associated with left ventricular mass in a gender-dependent manner. Kidney Blood Press Res 36:301–309
54.
go back to reference Orscelik O, Kocyigit I, Akpek ÞM, Dogdu O, Zengin H, Oymak O, Kaya MG (2013) Mean platelet volume and its relation with arterial stiffness in patients with normotensive polycystic kidney disease. J Investig Med 61:597–603CrossRefPubMed Orscelik O, Kocyigit I, Akpek ÞM, Dogdu O, Zengin H, Oymak O, Kaya MG (2013) Mean platelet volume and its relation with arterial stiffness in patients with normotensive polycystic kidney disease. J Investig Med 61:597–603CrossRefPubMed
55.
go back to reference Martinez-Vea A, Valero FA, Bardají Ruiz A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA (2000) Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20:193–200 Martinez-Vea A, Valero FA, Bardají Ruiz A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA (2000) Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20:193–200
56.
go back to reference Martinez-Vea A, Bardají A, Gutierrez C, García C, Peralta C, Marcas L, Oliver JA (2004) Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. Am J Kidney Dis 44:216–223CrossRefPubMed Martinez-Vea A, Bardají A, Gutierrez C, García C, Peralta C, Marcas L, Oliver JA (2004) Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: a prehypertensive state. Am J Kidney Dis 44:216–223CrossRefPubMed
57.
go back to reference Kelleher CL, McFann KK, Johnson AM, Schrier RW (2004) Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 17:1029–1034CrossRefPubMed Kelleher CL, McFann KK, Johnson AM, Schrier RW (2004) Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens 17:1029–1034CrossRefPubMed
58.
go back to reference Schrier RW, Johnson AM, McFann K, Chapman AB (2003) The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 64:1792–1799CrossRefPubMed Schrier RW, Johnson AM, McFann K, Chapman AB (2003) The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 64:1792–1799CrossRefPubMed
59.
go back to reference Van Der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T (2010) Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 55:1366–1372CrossRefPubMed Van Der Zwan LP, Scheffer PG, Dekker JM, Stehouwer CDA, Heine RJ, Teerlink T (2010) Hyperglycemia and oxidative stress strengthen the association between myeloperoxidase and blood pressure. Hypertension 55:1366–1372CrossRefPubMed
60.
go back to reference Grossman E (2008) Does increased oxidative stress cause hypertension? Diabetes Care 31:185–189CrossRef Grossman E (2008) Does increased oxidative stress cause hypertension? Diabetes Care 31:185–189CrossRef
61.
go back to reference Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255–2266CrossRefPubMedPubMedCentral Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB (2014) Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255–2266CrossRefPubMedPubMedCentral
62.
go back to reference Seeman T, Sikut M, Konrad M, Vondrichová H, Janda J, Schärer K (1997) Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr Nephrol 11:592–596CrossRefPubMed Seeman T, Sikut M, Konrad M, Vondrichová H, Janda J, Schärer K (1997) Blood pressure and renal function in autosomal dominant polycystic kidney disease. Pediatr Nephrol 11:592–596CrossRefPubMed
63.
go back to reference Seeman T, Dusek J, Vondrák K, Bláhová K, Simková E, Kreisinger J, Dvorák P, Kyncl M, Hríbal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629–634PubMed Seeman T, Dusek J, Vondrák K, Bláhová K, Simková E, Kreisinger J, Dvorák P, Kyncl M, Hríbal Z, Janda J (2004) Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53:629–634PubMed
64.
go back to reference Patch C, Charlton J, Roderick PJ, Gulliford MC (2011) Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 57:856–862CrossRefPubMed Patch C, Charlton J, Roderick PJ, Gulliford MC (2011) Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. Am J Kidney Dis 57:856–862CrossRefPubMed
65.
go back to reference Cadnapaphornchai MA, Mcfann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820–829CrossRefPubMedPubMedCentral Cadnapaphornchai MA, Mcfann K, Strain JD, Masoumi A, Schrier RW (2009) Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol 4:820–829CrossRefPubMedPubMedCentral
66.
go back to reference Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17–27CrossRefPubMedPubMedCentral Chapman AB, Devuyst O, Eckardt K-U, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC (2015) Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 88:17–27CrossRefPubMedPubMedCentral
67.
go back to reference Whelton PK, Carey RM, Aronow WS, Ovbiagele B, Casey DE, Smith SC, Collins KJ, Spencer CC, Himmelfarb CD, Stafford RS, Depalma SM, Taler SJ, Gidding S, Thomas RJ, Jamerson KA, Williams KA, Jones DW, Williamson JD, Maclaughlin EJ, Wright JT, Mauri L (2017) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:e13–e115 Whelton PK, Carey RM, Aronow WS, Ovbiagele B, Casey DE, Smith SC, Collins KJ, Spencer CC, Himmelfarb CD, Stafford RS, Depalma SM, Taler SJ, Gidding S, Thomas RJ, Jamerson KA, Williams KA, Jones DW, Williamson JD, Maclaughlin EJ, Wright JT, Mauri L (2017) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:e13–e115
68.
go back to reference Sag S, Yildiz A, Gullulu S, Gungoren F, Ozdemir B, Cegilli E (2016) Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima - media thickness. Springerplus 5:211–217CrossRefPubMedPubMedCentral Sag S, Yildiz A, Gullulu S, Gungoren F, Ozdemir B, Cegilli E (2016) Early atherosclerosis in normotensive patients with autosomal dominant polycystic kidney disease: the relation between epicardial adipose tissue thickness and carotid intima - media thickness. Springerplus 5:211–217CrossRefPubMedPubMedCentral
69.
go back to reference Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243–255CrossRefPubMed Chirinos JA (2012) Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 5:243–255CrossRefPubMed
70.
go back to reference Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Bae KT (2011) Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2508–2515CrossRefPubMedPubMedCentral Perrone RD, Abebe KZ, Schrier RW, Chapman AB, Torres VE, Bost J, Kaya D, Miskulin DC, Steinman TI, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Kelleher C, Masoumi A, Glockner J, Halin NJ, Martin D, Remer E, Patel N, Pedrosa I, Wetzel LH, Thompson PA, Miller JP, Meyers CM, Bae KT (2011) Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6:2508–2515CrossRefPubMedPubMedCentral
71.
72.
go back to reference Förstermann U, Li H (2011) Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164:213–223CrossRefPubMedPubMedCentral Förstermann U, Li H (2011) Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 164:213–223CrossRefPubMedPubMedCentral
73.
go back to reference Li H, Förstermann U (2013) Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 13:161–167CrossRefPubMed Li H, Förstermann U (2013) Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 13:161–167CrossRefPubMed
74.
go back to reference Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752–760CrossRefPubMed Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D (2006) Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 48:752–760CrossRefPubMed
75.
go back to reference Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42–50CrossRefPubMed Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C (2006) The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 47:42–50CrossRefPubMed
76.
go back to reference Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73:411–418CrossRef Higashi Y, Noma K, Yoshizumi M, Kihara Y (2009) Endothelial function and oxidative stress in cardiovascular diseases. Circ J 73:411–418CrossRef
77.
go back to reference Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2011) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6:7–13CrossRefPubMedPubMedCentral Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M (2011) Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease. Clin J Am Soc Nephrol 6:7–13CrossRefPubMedPubMedCentral
78.
go back to reference Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S (2013) Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Kidney Blood Press Res 38:72–82CrossRefPubMed Raptis V, Georgianos PI, Sarafidis PA, Sioulis A, Makedou K, Makedou A, Grekas DM, Kapoulas S (2013) Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease. Kidney Blood Press Res 38:72–82CrossRefPubMed
79.
go back to reference Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S (2004) The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 112:358–368CrossRefPubMed Wang D, Braendstrup O, Larsen S, Horn T, Strandgaard S (2004) The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats. APMIS 112:358–368CrossRefPubMed
80.
go back to reference Zhou M, Schuman I, Jaimes E, Raij L (2008) Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 295:F53–F59CrossRefPubMedPubMedCentral Zhou M, Schuman I, Jaimes E, Raij L (2008) Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 295:F53–F59CrossRefPubMedPubMedCentral
81.
go back to reference Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004–1010CrossRefPubMedPubMedCentral Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004–1010CrossRefPubMedPubMedCentral
82.
go back to reference Laufs U (2003) Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58:719–731CrossRefPubMed Laufs U (2003) Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58:719–731CrossRefPubMed
83.
go back to reference Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM (2013) Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 28:380–385 Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM (2013) Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant 28:380–385
84.
go back to reference Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O (2013) Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephron Clin Pract 123:157–164CrossRefPubMed Kocyigit I, Yilmaz MI, Orscelik O, Sipahioglu MH, Unal A, Eroglu E, Kalay N, Tokgoz B, Axelsson J, Oymak O (2013) Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Nephron Clin Pract 123:157–164CrossRefPubMed
85.
go back to reference Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol 37:e00337-17 Ishimoto Y, Inagi R, Yoshihara D, Kugita M, Nagao S, Shimizu A, Takeda N, Wake M, Honda K, Zhou J, Nangaku M (2017) Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol Cell Biol 37:e00337-17
86.
go back to reference Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman IE, Karumanchi SA, Rhee EP, Parikh SM (2016) PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531:528–532CrossRefPubMedPubMedCentral Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman IE, Karumanchi SA, Rhee EP, Parikh SM (2016) PGC1α drives NAD biosynthesis linking oxidative metabolism to renal protection. Nature 531:528–532CrossRefPubMedPubMedCentral
87.
go back to reference Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127:1109–1122CrossRefPubMed Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 127:1109–1122CrossRefPubMed
88.
go back to reference Zhou Y, Lin S, Zhang L, Li Y (2016) Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-α pathway. Mol Cell Biochem 411:143–150CrossRefPubMed Zhou Y, Lin S, Zhang L, Li Y (2016) Resveratrol prevents renal lipotoxicity in high-fat diet-treated mouse model through regulating PPAR-α pathway. Mol Cell Biochem 411:143–150CrossRefPubMed
89.
go back to reference Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690CrossRefPubMedPubMedCentral Price NL, Gomes AP, Ling AJY, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15:675–690CrossRefPubMedPubMedCentral
90.
go back to reference Wu M, Gu J, Mei S, Xu D, Jing Y, Yao Q, Chen M, Yang M, Chen S, Yang B, Qi N, Hu H, Wüthrich RP, Mei C (2016) Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κb-induced inflammation. Nephrol Dial Transplant 31:1826–1834CrossRefPubMed Wu M, Gu J, Mei S, Xu D, Jing Y, Yao Q, Chen M, Yang M, Chen S, Yang B, Qi N, Hu H, Wüthrich RP, Mei C (2016) Resveratrol delays polycystic kidney disease progression through attenuation of nuclear factor κb-induced inflammation. Nephrol Dial Transplant 31:1826–1834CrossRefPubMed
91.
go back to reference Chang M, Ong ACM (2017) Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:2144CrossRefPubMed Chang M, Ong ACM (2017) Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 32:2144CrossRefPubMed
92.
go back to reference Cadnapaphornchai MA, George DM, Masoumi A, Mcfann K, Strain JD, Schrier RW (2011) Effect of statin therapy on disease progression of pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 32:437–445CrossRefPubMedPubMedCentral Cadnapaphornchai MA, George DM, Masoumi A, Mcfann K, Strain JD, Schrier RW (2011) Effect of statin therapy on disease progression of pediatric ADPKD: design and baseline characteristics of participants. Contemp Clin Trials 32:437–445CrossRefPubMedPubMedCentral
93.
go back to reference Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889–896CrossRefPubMedPubMedCentral Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW (2014) Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 9:889–896CrossRefPubMedPubMedCentral
94.
go back to reference Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA (2015) Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 10:1534–1541CrossRefPubMedPubMedCentral Klawitter J, McFann K, Pennington AT, Wang W, Klawitter J, Christians U, Schrier RW, Gitomer B, Cadnapaphornchai MA (2015) Pravastatin therapy and biomarker changes in children and young adults with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 10:1534–1541CrossRefPubMedPubMedCentral
95.
go back to reference Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev 13:1–11 Brosnahan G, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE (2017) Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials. Curr Hypertens Rev 13:1–11
96.
go back to reference Beevers CS, Chen L, Liu L, Luo Y, Webster NJG, Huang S (2009) Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 69:1000–1008CrossRefPubMedPubMedCentral Beevers CS, Chen L, Liu L, Luo Y, Webster NJG, Huang S (2009) Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 69:1000–1008CrossRefPubMedPubMedCentral
97.
go back to reference Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225CrossRefPubMed Kunnumakkara AB, Anand P, Aggarwal BB (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269:199–225CrossRefPubMed
98.
go back to reference Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJM (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300:F1193–F1202CrossRefPubMed Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJM (2011) Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300:F1193–F1202CrossRefPubMed
99.
go back to reference Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, Yang B (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 654:92–99CrossRefPubMed Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, Yang B (2011) Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 654:92–99CrossRefPubMed
100.
go back to reference Kim BH, Lee ES, Choi R, Nawaboot J, Lee MY, Lee EY, Kim HS, Chung CH (2016) Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 57:664–673CrossRefPubMedPubMedCentral Kim BH, Lee ES, Choi R, Nawaboot J, Lee MY, Lee EY, Kim HS, Chung CH (2016) Protective effects of curcumin on renal oxidative stress and lipid metabolism in a rat model of type 2 diabetic nephropathy. Yonsei Med J 57:664–673CrossRefPubMedPubMedCentral
101.
go back to reference Ali BH, Al-Salam S, Suleimani Y, Kalbani J, Bahlani S, Ashique M, Manoj P, Dhahli B, Abri N, Naser HT, Yasin J, Nemmar A, Za’abi M, Hartmann C, Schupp N (2018) Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic Clin Pharmacol Toxicol 122:65–73CrossRefPubMed Ali BH, Al-Salam S, Suleimani Y, Kalbani J, Bahlani S, Ashique M, Manoj P, Dhahli B, Abri N, Naser HT, Yasin J, Nemmar A, Za’abi M, Hartmann C, Schupp N (2018) Curcumin ameliorates kidney function and oxidative stress in experimental chronic kidney disease. Basic Clin Pharmacol Toxicol 122:65–73CrossRefPubMed
102.
go back to reference Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192:233–242CrossRefPubMed Alhaider AA, Korashy HM, Sayed-Ahmed MM, Mobark M, Kfoury H, Mansour MA (2011) Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. Chem Biol Interact 192:233–242CrossRefPubMed
103.
go back to reference Zhang S, Xu H, Yu X, Wu Y, Sui D (2017) Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med 14:383–390CrossRefPubMedPubMedCentral Zhang S, Xu H, Yu X, Wu Y, Sui D (2017) Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes. Exp Ther Med 14:383–390CrossRefPubMedPubMedCentral
104.
go back to reference Mekahli D, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, Dechênes G, Ong ACM, Wilmer MJ, Van Den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H (2014) Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch Eur J Physiol 466:1591–1604 Mekahli D, Decuypere JP, Sammels E, Welkenhuyzen K, Schoeber J, Audrezet MP, Corvelyn A, Dechênes G, Ong ACM, Wilmer MJ, Van Den Heuvel L, Bultynck G, Parys JB, Missiaen L, Levtchenko E, De Smedt H (2014) Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin. Pflugers Arch Eur J Physiol 466:1591–1604
105.
go back to reference Takiar V, Nishio S, Seo-Mayer P, King JD, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462–2467CrossRefPubMedPubMedCentral Takiar V, Nishio S, Seo-Mayer P, King JD, Li H, Zhang L, Karihaloo A, Hallows KR, Somlo S, Caplan MJ (2011) Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 108:2462–2467CrossRefPubMedPubMedCentral
106.
go back to reference Chang MY, Ma TL, Hung CC, Tian YC, Chen YC, Yang CW, Cheng YC (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep 7:7161CrossRefPubMedPubMedCentral Chang MY, Ma TL, Hung CC, Tian YC, Chen YC, Yang CW, Cheng YC (2017) Metformin inhibits cyst formation in a zebrafish model of polycystin-2 deficiency. Sci Rep 7:7161CrossRefPubMedPubMedCentral
107.
go back to reference Marcum ZA, Forsberg CW, Moore KP, de Boer IH, Smith NL, Boyko EJ, Floyd JS (2018) Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease. J Gen Intern Med 33:155–165CrossRefPubMed Marcum ZA, Forsberg CW, Moore KP, de Boer IH, Smith NL, Boyko EJ, Floyd JS (2018) Mortality associated with metformin versus sulfonylurea initiation: a cohort study of veterans with diabetes and chronic kidney disease. J Gen Intern Med 33:155–165CrossRefPubMed
108.
go back to reference Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S (2011) PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300:465–474CrossRef Yoshihara D, Kurahashi H, Morita M, Kugita M, Hiki Y, Aukema HM, Yamaguchi T, Calvet JP, Wallace DP, Nagao S (2011) PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am J Physiol Renal Physiol 300:465–474CrossRef
109.
go back to reference Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S (2002) Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731–1742CrossRefPubMed Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K, Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S (2002) Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 11:1731–1742CrossRefPubMed
110.
go back to reference Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J, Wang L, Lu C, Wang D (2016) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, ameliorates chronic kidney disease by enhancing antioxidative capacity and attenuating angiogenesis in the kidney of a 5/6 nephrectomized rat model. Cell Physiol Biochem 38:1831–1840CrossRefPubMed Sun L, Yuan Q, Xu T, Yao L, Feng J, Ma J, Wang L, Lu C, Wang D (2016) Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, ameliorates chronic kidney disease by enhancing antioxidative capacity and attenuating angiogenesis in the kidney of a 5/6 nephrectomized rat model. Cell Physiol Biochem 38:1831–1840CrossRefPubMed
Metadata
Title
Oxidative stress in autosomal dominant polycystic kidney disease: player and/or early predictor for disease progression?
Authors
Asmin Andries
Kristien Daenen
François Jouret
Bert Bammens
Djalila Mekahli
Ann Van Schepdael
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 6/2019
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-018-4004-5

Other articles of this Issue 6/2019

Pediatric Nephrology 6/2019 Go to the issue